Compare Johnson & Johnson (JNJ) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Johnson & Johnson trades at $250.04 (market cap $598.96B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.82. The key difference: Johnson & Johnson pays a 2.15% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | RDTE | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Income / Options Overlay |
52-Week High | $267.24 | $34.72 |
52-Week Low | $164.36 | $26.40 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
RDTE trades at $28.57, down 0.38% with a bearish technical signal. The stock exhibits high dividend activity but lacks disclosed valuation and profitability ratios. Recent news highlights structural risks in its covered call strategy, with concerns about capital erosion despite high yields. Trading near support at $28, the stock faces selling pressure from moving averages while oscillators show neutral to oversold conditions.
The outlook remains cautious due to unresolved fundamental metrics and negative analyst sentiment. Investment opportunities hinge on dividend sustainability, but risks include capped upside from the options strategy and potential NAV deterioration. Investors require clearer financial disclosures to assess true value amid bearish technical and media coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
